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the lifespan of erythrocytes leading to volume changes. [6] Among patients with DM, increased RDW levels indicate poor glycemic control. [7, 8] In our study, we have attempted to investigate the possible differences in variables such as RDW and EFT thickness between diabetic and healthy patients and to assess the correlation (if any) between those parameters.
materIals and metHods
One hundred and fifty-nine type II diabetic patients and 153 healthy counterparts were enrolled in this single-center, prospective study. The study was approved by Kafkas University Medical Faculty ethical commitee (ethical committee number: 80576354-050-99, approval date: 14/03/2008). Clinical and demographic variables, medical history, and concomitant medications of the patients were measured at baseline. Data regarding diabetes duration and medications taken by the diabetic patients were also recorded. Diagnosis of type II DM was made according to the American Diabetes Association criteria. [9] Patients with anemia (hemoglobin <12 g/dl), chronic renal failure, obesity, congestive heart failure, active infection, chronic inflammatory diseases, malignancy, history of coronary artery bypass graft or percutaneous intervention, previous myocardial infarction, and stable or unstable angina were excluded from the study.
Fasting blood samples were drawn from the antecubital vein with the patient resting in the supine position. All specimens were analyzed on the same day in the biochemistry laboratory. Biochemical analysis was performed by Cobas c311 (Roche Diagnostics, Germany) and the following parameters were measured: fasting glucose, hemoglobin A1c, C-reactive protein, creatinine, total cholesterol, high-density lipoprotein cholesterol (HDL-C), triglyceride (TG), and low-density lipoprotein cholesterol (LDL-C). The blood parameters of all participants including hemoglobin, RDW, and platelet count, were studied by Cell-Dyn 3700 (Abbott Laboratories, Abbott Park, Illinois, USA).
All patients had 12-lead resting electrocardiogram in the supine position and had complete echocardiographic examination (Vivid 3 pro, GE Vingmed Ultrasound AS, Horten, Norway). The same cardiologist who was blinded to the clinic of the patients was performed the echocardiographic examination based on the recommendations of the American Society of Echocardiography. [10] Simpson rule was used for calculating the left ventricular ejection fraction (LVEF). EFT was appeared as the hyperechoic space in the anterior face of the right ventricle, and its thickness was measured perpendicularly ahead of the right ventricular free wall, at the end-diastole from the parasternal long-and short-axis views. [11] Continuous variables were presented as mean and standard deviation. Categorical variables were reported as percentages. Student's t-test was used to compare the parametric continuous variables. Nonparametric continuous variables and categorical variables were compared by Mann-Whitney U-test and Chi-square test, respectively. Pearson's correlation test was used to examine the correlation between the variables. For the cutoff values RDW and EFT, ROC curve analysis was used. All confidence intervals were 95%. P < 0.05 was regarded as statistically significant. All statistical analyses were performed using the SPSS program v. 15.0 (SPSS Inc., Chicago, IL, USA).
results
The study sample consisted of 312 patients. Among 159 diabetic patients, 65 were male, 94 were female, and among 153 control patients, 67 were male and 86 were female. Clinical characteristics of the patients such as age, sex, smoking, body mass index (BMI), systolic blood pressure, and LVEF were similar between the two groups. All the patients were on sinus rhythm during the study entry. Diastolic blood pressure of the diabetic patients was significantly higher than the healthy participants [ Table 1 ].
Diabetic patients had increased EFT thickness (4.3 ± 1.1 mm vs. 3.7 ± 1.0 mm P = 0.001), higher RDW values (13.5 ± 0.7 vs. 13.2 ± 0.7 P = 0.001), LDL-C, TG, and HgA1c levels compared to their healthy counterparts. Although HDL-C value was found to be higher in the control group, it did not carry statistical significance. The results of the serum biochemistry and hematological indices are shown in Table 2 .
On correlation analysis, RDW and EFT (0.384, P < 0.001) were strongly positively correlated. RDW was also positively correlated with LDL-C, TG, and HgA1c levels and negatively correlated with HDL-C level. Parameters that are correlated with RDW are listed in Table 3 . RDW value of 13.55 predicted EFT thickness >5 mm with a sensitivity of 61.7% and specificity of 58.8% (P: 0.001, Area under the curve [AUC]: 0.649, CI 95%: 0.564-0.733) [ Figure 1 ]. HgA1C value of >7 predicted EFT thickness ≥4.15 mm with a sensitivity of 60.7% and specificity of 60.4% (AUC: 0.651 vs. P < 0.001) [ Figure 2 ]. According to the power analysis, the strength to EFT in predicting the diabetic patients (alpha value = 0.05 and 95% confidence) was 99.9%.
dIscussIon
Our study showed that EFT thickness increased in diabetic patients, independent of age, gender, waist circumference, BMI, and it was correlated with RDW. As far as our best knowledge from the literature, our study is the first study showing a positive relation between EFT thickness and RDW in diabetic patients. EFT has both paracrine and vasocrine activities and secretes a range of chemokines such as tumor necrosis factor-α, interleukin-6, interleukin-1b, monocyte chemoattractant protein-1, angiotensin II, and resistin. [2, 12, 13] It has been suggested to influence atherosclerotic lesion progression, plaque vulnerability, and destabilization. [14] Echocardiographic-and computed tomography (CT)-derived measurements of the epicardial adipose tissue (EAT) thickness have been found to be in correlation with the fasting blood glucose levels. [15] Diabetic patients have increased EFT thickness as compared to nondiabetic participants, and it has a positive correlation with HbA1c levels. [16] Arpaci et al. [17] reported that prediabetic patients had higher EFT values which were directly correlated with the patients' BMI and waist circumference. Another study led by Altın et al. [18] investigated the relationship between fasting glucose levels and EFT and carotid intima-media thickness (CIMT) in prediabetic patients. In that study, prediabetic patients had higher EFT and CIMT, indicating that these two cardiovascular risk parameters could be used for risk stratification in that patient group. Studies have found positive relationship between EAT thickness and plasma level of insulin, retinol binding protein 4, and mRNA expression of resistin which are associated with insulin resistance. [19] [20] [21] EFT might be a modifiable risk factor or a target to modify cardiovascular risk. EFT and CIMT values of the asymptomatic obese patients were shown to be decreased after significant weight loss. [22] Weight loss reverses the insulin resistance and decrease of EAT thickness in patients with metabolic syndrome. [19] Serial measurement of EFT during follow-up of the patients may give additional information about their cardiovascular risk profile.
RDW is an indicator of erythrocyte anisocytosis, can be easily calculated from complete blood count. It has been found to have prognostic value in several diseases, such as coronary artery disease, left ventricular systolic failure, cerebrovascular disease, and chronic obstructive pulmonary disease. [23] [24] [25] Chronic inflammation underlying these diseases cause erythrocyte deformability and ineffective erythropoiesis which in turn leads to anisocytosis (high RDW). [4] Diabetic patients have higher RDW values when compared with normal participants. [26] Chronic hyperglycemia occurring in DM has several effects on erythrocytes, including glycosylation of hemoglobin, [27] impaired deformability, increased aggregation, and decreased circulatory half-life. [6] Nada. [26] reported that RDW levels were significantly high in diabetic patients than in control subjects and it was positively correlated with HbA1c levels.
EFT volume is higher in males, elderly, obese persons, as well as in diabetic and metabolic syndrome patients. [28] [29] [30] Although our study and control group were similar with respect to their age, sex, and BMI values, diabetic patients had an increased EFT thickness, which showed a correlation with RDW. The cytokines secreted by EFT affect erythropoiesis, erythrocyte volume, erythrocyte lifespan, and thus promoting anisocytosis (high RDW). [31] [32] [33] It is known that glycosylation of the hemoglobin reduces the lifespan of the erythrocytes. [7, 8] It can be speculated that, hormonal activity of EFT, glycosylation of hemoglobin, and increased oxidative stress in diabetic patients could cause RDW level elevation. DM is a metabolic disease which imposes substantial socioeconomic burden as a result of its complications. We showed that type II diabetic patients had higher EFT thickness and RDW levels when we compared them with the normal individuals. Moreover, EFT thickness was positively correlated with RDW. It has been shown that both EFT and RDW have prognostic value for ischemic heart disease, in-stent restenosis, congestive heart failure, and peripheral arterial disease. Therefore, measurement of EFT thickness and RDW in patients with DM may provide additional prognostic information.
Limitations
The limitations of the study include the following: (1) It was a single-center study; (2) the study contained a relatively small number of patients; (3) EFT thickness was not measured by multislice CT and/or magnetic resonance imaging in our study patients; (4) we did not separate the diabetic patients according to their medical treatment. Hence, we could not compare the patients in two groups with insulin therapy or only oral antidiabetics; and (5) we did not evaluate the duration of disease, we could not make the correlation analysis between disease duration and EFT.
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